Our Take
UCB is paying premium prices to license Chinese biotech work rather than develop internal capabilities in bispecifics.
Why it matters
Big pharma is increasingly relying on Chinese biotech innovation for next-generation autoimmune treatments. The $2.2B price tag signals serious confidence in bispecific antibodies as autoimmune therapies.
Do this week
Biotech executives: audit your China licensing deals before Q1 2025 so you can capitalize on increased Big Pharma interest in Asian biotech partnerships.
UCB acquired Candid for $2.2B to access Chinese bispecifics
Belgian pharmaceutical company UCB announced a $2.2 billion acquisition of Candid Therapeutics, gaining access to a portfolio of antibody drugs that Candid had previously licensed from China-based biotechnology companies.
The deal centers on bispecific antibodies designed to treat autoimmune diseases. UCB characterized these therapies as representing the "next wave" of care for immunological conditions (per BioPharma Dive reporting).
The acquisition gives UCB immediate access to drug candidates that originated from Chinese biotech companies, rather than developing these capabilities internally through its own research programs.
Western pharma is buying Chinese biotech innovation
The acquisition reflects a broader trend of established pharmaceutical companies acquiring access to Chinese biotech innovation through intermediary licensing deals. Rather than direct partnerships with Chinese companies, UCB chose to acquire Candid as a vehicle for accessing this technology.
Bispecific antibodies represent a growing class of treatments that can simultaneously target two different proteins, potentially offering more precise therapeutic effects than traditional monoclonal antibodies. For autoimmune diseases, this dual-targeting approach could provide better efficacy with reduced side effects.
The $2.2 billion valuation suggests UCB sees significant commercial potential in these licensed assets, particularly given that Candid served primarily as a licensing vehicle rather than conducting extensive internal drug development.
License holders gain leverage in Big Pharma deals
The deal demonstrates that companies holding licenses to promising Chinese biotech assets have become attractive acquisition targets for major pharmaceutical companies seeking to expand their pipelines without direct China exposure.
For biotech executives, the transaction establishes a precedent for valuations of China-licensed assets in the autoimmune space. Companies with similar licensing arrangements may find increased interest from strategic acquirers.
The acquisition also signals that bispecific antibodies for autoimmune diseases have moved from experimental treatments to assets worthy of billion-dollar investments by major pharmaceutical companies.